Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

By Simon Mallal, D. Nolan, C. S. Witt, G. Masel, Annalise M. Martin, C. Moore, D. Sayer, A. Castley, Cyril D Mamotte, D. Maxwell and 2 more. The Lancet, 2002

1,402 citations recorded by the source corpus.

Subfields: Dermatology, Infectious Diseases, Pharmacology

View Paper: https://www.semanticscholar.org/paper/342b698db17ad327fd12c08bb55ba1c4546ef691

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

M. McCormack

In Pharmacology

Citations in the corpus

Moving towards individualized medicine with pharmacogenomics (2004, background): “For example, patients at high risk of abacavir hypersensitivity can be identified on the basis of their HLA-B genotype”
International Consensus on drug allergy (2014, background): “4%) (48) in the Australian cohort, but lower (22.”
HLA-A★3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans (2011, background): “The most prominent example thus far is the strong predictive value of the HLA-B*5701 allele for hypersensitivity to the drug abacavir, used for the treatment of human immunodeficiency virus infection.(25,26,29) FDA guidelines now recommend HLA-B*5701 testing in advance of abacavir prescription.”
Uncovering the roles of rare variants in common disease through whole-genome sequencing (2010, background): “In another example, the frequency of the risk factor human leukocyte antigen-B*5701 ( HLA-B*5701 ) is increased as much as 30-fold in individuals who are hypersensitive to the antiretroviral drug abacavir compared with the general populatio”
Systems Pharmacology: Network Analysis to Identify Multiscale Mechanisms of Drug Action (2012, background): “Other examples in which a genotype–drug response phenotype is known but the underlying mechanism is not fully understood include patients with variants in major histocompatibility complex class IB (HLA-B*5701) who show hypersensitivity to the antiviral drug abacavir (43) and musculoskeletal toxicity”